索磷布韦和达卡他韦治疗2019冠状病毒病的综述
A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019.
作者信息
Shabani M, Sadegh Ehdaei B, Fathi F, Dowran R
机构信息
Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Microbiology and Immunology Department, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
出版信息
New Microbes New Infect. 2021 Jul;42:100895. doi: 10.1016/j.nmni.2021.100895. Epub 2021 May 7.
Abstract
Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae. Homology between hepatitis C virus RNA polymerase and severe acute respiratory syndrome coronavirus 2 has also been established. The efficacy of sofosbuvir and daclatasvir as potential choices in treating patients with coronavirus disease 2019 and their recovery can be hypothesized.
摘要
自2013年以来，索磷布韦和达卡他韦已成功用于丙型肝炎治疗。不同研究表明，索磷布韦可抑制包括黄病毒科和披膜病毒科在内的其他正链RNA病毒的RNA聚合酶。丙型肝炎病毒RNA聚合酶与严重急性呼吸综合征冠状病毒2之间的同源性也已得到证实。可以推测索磷布韦和达卡他韦作为治疗2019冠状病毒病患者的潜在选择及其疗效。
相似文献
1
A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019.
New Microbes New Infect. 2021 Jul;42:100895. doi: 10.1016/j.nmni.2021.100895. Epub 2021 May 7.
2
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.
J Antimicrob Chemother. 2021 Jun 18;76(7):1874-1885. doi: 10.1093/jac/dkab072.
3
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
J Antimicrob Chemother. 2020 Nov 1;75(11):3366-3372. doi: 10.1093/jac/dkaa331.
4
Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis.
J Clin Exp Hepatol. 2018 Mar;8(1):15-22. doi: 10.1016/j.jceh.2017.06.006. Epub 2017 Jun 30.
5
Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
Arch Med Res. 2020 Aug;51(6):577-581. doi: 10.1016/j.arcmed.2020.04.018. Epub 2020 Apr 29.
6
Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
Curr Drug Saf. 2020;15(1):53-60. doi: 10.2174/1574886314666191001151314.
7
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Sci Rep. 2020 Oct 6;10(1):16577. doi: 10.1038/s41598-020-73641-9.
8
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
J Hepatol. 2017 Jan;66(1):39-47. doi: 10.1016/j.jhep.2016.08.021. Epub 2016 Sep 10.
9
Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.
J Antimicrob Chemother. 2021 Jan 19;76(2):286-291. doi: 10.1093/jac/dkaa418.
10
Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
Nephrol Dial Transplant. 2021 Sep 27;36(10):1867-1871. doi: 10.1093/ndt/gfaa187.
引用本文的文献
1
UPLC-PDA factorial design assisted method for simultaneous determination of oseltamivir, dexamethasone, and remdesivir in human plasma.
Sci Rep. 2024 Sep 18;14(1):21758. doi: 10.1038/s41598-024-71413-3.
2
Insights into COVID-19: Perspectives on Drug Remedies and Host Cell Responses.
Biomolecules. 2023 Sep 26;13(10):1452. doi: 10.3390/biom13101452.
3
Severe COVID-19: Drugs and Clinical Trials.
J Clin Med. 2023 Apr 16;12(8):2893. doi: 10.3390/jcm12082893.
4
Assessment of binding interaction to salmon sperm DNA of two antiviral agents and ecofriendly nanoparticles: comprehensive spectroscopic study.
BMC Chem. 2023 Apr 19;17(1):39. doi: 10.1186/s13065-023-00952-z.
5
Development of UPLC method for simultaneous assay of some COVID-19 drugs utilizing novel instrumental standard addition and factorial design.
Sci Rep. 2023 Apr 4;13(1):5466. doi: 10.1038/s41598-023-32405-x.
6
Renin-Angiotensin-Aldosterone Axis Inhibition Improves Outcome of Diabetic Patients with Chronic Hypertension and COVID-19: An Iranian Perspective.
Adv Biomed Res. 2022 Dec 26;11:109. doi: 10.4103/abr.abr_177_21. eCollection 2022.
7
Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics.
Mol Aspects Med. 2023 Jun;91:101151. doi: 10.1016/j.mam.2022.101151. Epub 2022 Oct 28.
8
Dibenzo-18-crown-6-based carbon paste sensors for the nanomolar potentiometric determination of daclatasvir dihydrochloride: An anti-HCV drug and a potential candidate for treatment of SARS-CoV-2.
Microchem J. 2022 Jun;177:107276. doi: 10.1016/j.microc.2022.107276. Epub 2022 Feb 10.
本文引用的文献
1
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.
J Antimicrob Chemother. 2021 Jun 18;76(7):1874-1885. doi: 10.1093/jac/dkab072.
2
Nucleotide analogues as inhibitors of SARS-CoV Polymerase.
Pharmacol Res Perspect. 2020 Dec;8(6):e00674. doi: 10.1002/prp2.674.
3
Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.
J Proteome Res. 2020 Nov 6;19(11):4690-4697. doi: 10.1021/acs.jproteome.0c00392. Epub 2020 Aug 5.
4
Sofosbuvir as a potential option for the treatment of COVID-19.
Acta Biomed. 2020 May 11;91(2):236-238. doi: 10.23750/abm.v91i2.9609.
5
Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
Arch Med Res. 2020 Aug;51(6):577-581. doi: 10.1016/j.arcmed.2020.04.018. Epub 2020 Apr 29.
6
In silico studies on therapeutic agents for COVID-19: Drug repurposing approach.
Life Sci. 2020 Jul 1;252:117652. doi: 10.1016/j.lfs.2020.117652. Epub 2020 Apr 9.
7
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Drug Discov Ther. 2020;14(1):58-60. doi: 10.5582/ddt.2020.01012.
8
Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China.
Cell Host Microbe. 2020 Mar 11;27(3):325-328. doi: 10.1016/j.chom.2020.02.001. Epub 2020 Feb 7.
9
A pneumonia outbreak associated with a new coronavirus of probable bat origin.
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
10
Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.
J Virol. 2020 Mar 17;94(7). doi: 10.1128/JVI.00127-20.
Zotero 插件